China's vaccine regulatory system has been evaluated by the World Health Organization

On August 23, 2022, the World Health Organization (WHO) announced that China has passed the National Regulatory System (NRA) assessment for vaccines

The WHO's assessment of the national vaccine regulatory system is an important measure and effective means for the assessment of the national vaccine regulatory capacity, and is a world-wide international assessment

Through the assessment, it not only means that China has a stable, well-run and complete and unified regulatory system, which can ensure that the quality of vaccines produced, imported or circulated in China is controllable, safe and effective, but also an important foundation for

Since China first passed the evaluation of the national vaccine regulatory system, there are many vaccines such as domestic Japanese encephalitis live attenuated vaccine, type I polio live attenuated vaccine, hepatitis A inactivated vaccine through the WHO vaccine pre-certification, entered the international procurement list, and was purchased by UNICEF, the Global Alliance for Vaccines and Immunization and other international institutions, and related products have been exported to dozens of countries and regions

The WHO evaluation of China's vaccine regulatory system highlights the improvement of China's vaccine regulatory system against international standards, regulatory capabilities and levels, which can ensure the safety, effectiveness and controllable quality of vaccine products, so as to better protect people's health, and also create good conditions